You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

the selective progesterone receptor modulators

Showing 1 - 25 of 9,952
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Leiomyoma Trial run by the NICHD (ulipristal acetate 20 mg, ulipristal acetate 10 mg, )

Completed
Has Results
  • Leiomyoma
  • ulipristal acetate 20 mg
  • +2 more
  • Bethesda, Maryland
  • +1 more
Feb 14, 2022

HIV Trial in Puerto Rico, United States (Tamoxifen, Vorinostat, Antiretroviral drugs)

Active, not recruiting
Has Results
  • HIV Infections
  • Birmingham, Alabama
  • +13 more
Jan 13, 2022

Fibroids Before and During Non-surgical Therapy and/or Expectant

Recruiting
  • Fibroid Uterus
  • Questionnaire
  • Amsterdam, Noord-Holland, Netherlands
    Amsterdam UMC
Feb 21, 2023

Androgen Receptor Positive, Estrogen Receptor Negative, HER2/Neu Negative Trial in United States (drug, other, biological)

Active, not recruiting
Has Results
  • Androgen Receptor Positive
  • +5 more
  • Corona, California
  • +6 more
Jun 8, 2022

Schizophrenia, Schizoaffective Disorder Trial in Melbourne (Raloxifene HCl, Placebo)

Completed
  • Schizophrenia
  • Schizoaffective Disorder
  • Raloxifene hydrochloride
  • Placebo
  • Melbourne, Victoria, Australia
    Monash Alfred Psychiatry Research Centre
Jan 6, 2020

Missed Abortion, Anembryonic Pregnancy, Non-Viable Pregnancy Trial in Chapel Hill, Hillsborough (Ulipristal Acetate Tablets,

Recruiting
  • Missed Abortion
  • +2 more
  • Ulipristal Acetate Tablets
  • Misoprostol Pill
  • Chapel Hill, North Carolina
  • +3 more
Jun 9, 2022

Myomectomy vs Uterine Artery Embolization vs GnRh Antagonist for

Active, not recruiting
  • Heavy Menstrual Bleeding
  • Fibroid Uterus
  • Groups 1 and 2 myomectomy and uterine artery embolization, respectively, are surgical/procedure
  • Elagolix Oral Product
  • Washington, District of Columbia
    MedStar Washington Hospital Center
Apr 29, 2022

Schizophrenia, Schizoaffective Disorder, Schizophreniform Disorder Trial in Melbourne (Raloxifene Hydrochloride, Placebo)

Unknown status
  • Schizophrenia
  • +2 more
  • Raloxifene Hydrochloride
  • Placebo
  • Melbourne, Victoria, Australia
    Alfred Hospital
Jan 6, 2020

PTSD Trial in San Francisco (CORT108297, Placebo)

Not yet recruiting
  • PTSD
  • San Francisco, California
    San Francisco VA Medical Center, San Francisco, CA
Jul 26, 2022

Leiomyoma Trial run by the NICHD (CDB-2914)

Completed
  • Leiomyoma
  • Bethesda, Maryland
    National Institutes of Health Clinical Center, 9000 Rockville Pi
Dec 14, 2019

Perimenopause-Related Mood and Behavioral Disorders

Recruiting
  • Mood Disorder
    • Bethesda, Maryland
      National Institutes of Health Clinical Center
    Jan 27, 2023

    Increased Risk for Development of Breast Cancer Trial in Kansas City (bazedoxifene plus conjugated estrogens)

    Recruiting
    • Increased Risk for Development of Breast Cancer
    • bazedoxifene plus conjugated estrogens
    • Kansas City, Kansas
      University of Kansas Medical Center
    Jan 9, 2022

    Schizophrenia Trial in Shanghai (Raloxifene Hydrochloride, Placebo)

    Completed
    • Schizophrenia
    • Raloxifene Hydrochloride
    • Placebo
    • Shanghai, Minhang, China
      CHINA
    Sep 4, 2019

    Inhibitory Neurotransmission in the Human Epileptic Brain.

    Recruiting
    • Drug Resistant Epilepsy
    • ex-vivo study
    • Pozzilli, Isernia, Italy
      IRCCS INM Neuromed
    Jul 29, 2022

    Breast Cancer Trial in Canada (Diagnostic Imaging: 18F-FDG PET/CT Scan - Baseline, Diagnostic Imaging: 18F-FES PET/CT -

    Terminated
    • Breast Cancer
    • Diagnostic Imaging: 18F-FDG PET/CT Scan - Baseline
    • +2 more
    • Kelowna, British Columbia, Canada
    • +3 more
    Nov 15, 2021

    Focus of Study is Healthy Women at Risk for Breast Cancer Trial in Kansas City (DUAVEE 0.45Mg-20Mg Tablet)

    Terminated
    • Focus of Study is Healthy Women at Risk for Breast Cancer
    • DUAVEE 0.45Mg-20Mg Tablet
    • Kansas City, Kansas
      University of Kansas Medical Center
    Oct 22, 2021

    Clomiphene Citrate asInhibitor of Ovulation inOocyte

    Not yet recruiting
    • Infertility, Female
    • Infertility
    • Baton Rouge, Louisiana
      Womans Hospital
    May 17, 2023

    Cyclin-dependent Kinase Inhibitor 2A on Labor-related Signals

    Not yet recruiting
    • Preterm Labor
      • (no location specified)
      May 9, 2023

      A Post-Authorization, Long-term Study of Ozanimod Real-world

      Active, not recruiting
      • Multiple Sclerosis, Relapsing-Remitting
        • Bethesda, Maryland
          Evidera
        Oct 31, 2022

        Multiple Sclerosis COVID-19/Vaccination Treated With Ofatumumab

        Completed
        • Multiple Sclerosis
          • East Hanover, New Jersey
            Novartis
          Jul 14, 2023

          Breast Cancer, Triple Negative Breast Cancer, HER2+ Breast Cancer Trial run by the NCI (Brachyury-TRICOM, Entinostat, M7824)

          Terminated
          Has Results
          • Breast Cancer
          • +4 more
          • Brachyury-TRICOM
          • +3 more
          • Bethesda, Maryland
            National Institutes of Health Clinical Center
          Dec 9, 2021

          Breast Cancer, Breast Cancer, Early-Onset Trial (Giredestrant, Tamoxifen)

          Not yet recruiting
          • Breast Cancer
          • Breast Cancer, Early-Onset
          • (no location specified)
          Jan 18, 2023

          Primary Aldosteronism, Hypertension Trial (Finerenone, Spironolactone)

          Not yet recruiting
          • Primary Aldosteronism
          • Hypertension
          • (no location specified)
          Apr 3, 2023

          Prostate Cancer Trial in Gainesville, Baltimore, Boston (LY2452473, Placebo)

          Completed
          Has Results
          • Prostate Cancer
          • Gainesville, Florida
          • +3 more
          Sep 27, 2021

          Toremifene, Tamoxifen, and Aromatase Inhibitor Plus Ovarian

          Not yet recruiting
          • Hormone-receptor-positive Breast Cancer
          • +3 more
          • Aromatase inhibitor
          • +3 more
          • Guangzhou, Guangdong, China
            Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
          Apr 5, 2023